A multi-center, open-label, single-dose, single-arm study to evaluate the usability of subcutaneously administered sumatriptan [DosePro; Zogenix] delivered via the Intraject system in adult patients during acute migraine attack

Trial Profile

A multi-center, open-label, single-dose, single-arm study to evaluate the usability of subcutaneously administered sumatriptan [DosePro; Zogenix] delivered via the Intraject system in adult patients during acute migraine attack

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2007

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Zogenix
  • Most Recent Events

    • 04 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top